Healio3h
One-year data confirm efficacy of high-fluence accelerated epi-off cross-linking
One-year data of high-fluence accelerated epithelium-off corneal cross-linking for keratoconus showed efficacy comparable to ...
‘Irreversible’ eye damage fixed by stem cells in human trial
Researchers successfully pulled off the first eye stem cell transplants to help heal cornea damage, and the results speak for ...
Harvard Medical School9d
Stem Cell Therapy Repairs Cornea Damage Thought Irreversible
The cornea is the clear, outermost layer of the eye. Its outer border, the limbus, contains a large volume of healthy stem ...
Targeted Oncology5h
FDA Backs Phase 3 Trial of Pro-ocular for Ocular GVHD Treatment
A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease. Signal12 ...
Daily Excelsior3d
Swami Vivekananda Hospital starts Corneal Transplant Surgery
Correspondent JAMMU, Mar 15 Swami Vivekananda Medical Mission Charitable Hospital (SVMMCH), Ambphalla here has started the ...
Ophthalmology Times9d
OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain
Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...
Clinical Pain Advisor6d
OKYO Pharma Seeks Fast Track for Urcosimod in Neuropathic Corneal Pain
OKYO Pharma has filed a Fast Track designation application for urcosimod in the treatment of neuropathic corneal pain.